摘要
目的评价伊贝沙坦和培哚普利对老年高血压病人的降压疗效及安全性,尤其是对坐位舒张压的影响.方法选用住院的1～2级高血压病人212例,服培哚普利为对照组106例,4 mg/d,服伊贝沙坦为试验组106例,150 mg/d,服药后第3天、第2、4、6周和第8周,分别观察其血压变化、自觉症状和有关实验室检查,第4周谷值坐位舒张压高于90 mmHg者,加服吲哒帕胺 1.25 mg/d.结果除尿酸升高外,治疗前和治疗8周后在血生化、肝酶和血脂等方面均无统计学差别,收缩压(SBP)在治疗后第4周,舒张压(DBP)在第6周降到正常,并一直稳定到第 8周.2组治疗后不同时期与治疗前相比,SBP和DBP均相差显著.加用吲哒帕胺的病例在第6周平均谷值坐位DBP进一步下降并相差显著.治疗后试验组总有效率81.2%,对照组79.6%,试验组显效率、有效率均高于对照组,并有统计学意义,P＜0.05.对照组中咳嗽明显高于试验组,相差非常显著.结论伊贝沙坦和培哚普利均能有效控制和稳定血压,尤其在加用小剂量吲哚帕胺后,对谷值坐位DBP高者.但伊贝沙坦降低24 h后谷值舒张压作用更好一些,不良反应更少.
Objective To evaluate the efficacy and safety of irbesartan and perindopril in senile patients with hypertension,especially with high DBP. Methods Two hundred and twelve senile patients with level 1 to 2 hypertension were randomly assigned to receiving 150 mg/d irbesartan as treatment group (n=106) for 8 weeks.A trough sitting DBP and SBP were measured before and biweekly after medication.Adverse events and blood biochemical tests were recorded before and after drug treatment.Indopamide 1.25 mg/d was added to the patients whose DBP was >90 mmHg at the fourth week of study. Results Except hyperuricemia,there were no differences between two groups in blood biochemical test before and after 8 weeks(P>0.05).SBP at the fourth week and DBP at the sixth week reduced to normal and kept steady until the eighth week.SBP and a trough sitting DBP decreased more significantly in both groups in different treating stages than before(P<0.01).A trough sitting DBP continually decreased at the sixth week in the patients added by indapamide.The total response rate was 81.2% in irbesartan group and 79.6% in perindopril group (P<0.05).Cough was more often found in perindopril group than that in irbesartan group (P<0.01). Conclusions Irbesartan and perindopril are effective and safe in treatment of hypertension,and more effective accompanied with indapamide,especially for patients with high DBP.Irbesartan seems to be more effective in the reduction of DBP and has less adverse events than perindopril.
出处
《实用老年医学》
CAS
2005年第1期28-31,共4页
Practical Geriatrics
